Risk factors

Construction and financing risks dominate, highlighted by a $25.0 million common stock purchase agreement with Roth Principal Investments. Dividend payments remain suspended while management focuses on debt repayment and share buybacks.

Biote expanded disclosures on supply chain reliance, tariffs, inventory management, restructuring, and commercial agreements. The company added new risks regarding trade policies affecting material sourcing like estradiol from China and trocars from Pakistan. Disclosures now reflect the acquisition of Asteria Health and the termination notice from partner AnazaoHealth.

Bank failures and digital deposit withdrawals heighten liquidity risk and could force securities sales at losses.

CB Financial Services streamlined technology risk disclosures while emphasizing potential credit losses from inflation and real estate market disruptions.

The company has not completed its initial business combination and faces an August 8, 2026 deadline.

Revenue dropped to $14,825 in 2025 with net losses of $6,498,167 and an accumulated deficit of $29,250,000.

Chemung Financial Corp added subordinated debt risks following $45.0 million in June 2025 notes issuance. Inflation and Federal Reserve policy risks were updated with 2025 metrics. Technological risk now accounts for the GENIUS Act passed in July 2025.

Unrealized investment losses decreased to $90.4 million at year-end 2025. Commercial and construction real estate loans grew significantly to $1.8 billion. Commercial and industrial loan balances rose to $352.6 million.

Insight Digital Partners II is a blank check company seeking an initial Business Combination without prior shareholder approval rights. The company faces strict completion windows, redemption risks, and potential complexities from cross-border or out-of-sector targets. Operations depend heavily on sponsor support and trust account protections against third-party claims.

Elutia sold its entire cardiac device business on October 1, 2025, shifting its future results to rely on Women's Health, NXT-41x, and Cardiovascular products. The company received Nasdaq deficiency notices regarding its minimum bid price below $1.00 and market value requirements.

Severe liquidity constraints and a negative working capital of $16.2 million raise going concern doubts.

The company addressed Nasdaq continued listing requirements after receiving a deficiency notice, noting equity dropped to approximately $2.4 million before a $9.5 million public offering.